新血府逐瘀软胶囊对冠心病患者血瘀征象及血管内皮炎症的影响

Effect of New Xuefu Zhuyu Soft Capsule on the Blood Stasis Syndrome and Vascular Endothelial Inflammation in Patients with Coronary Heart Disease

目的探讨新血府逐瘀软胶囊对冠心病(CHD)患者血瘀征象、脂质过氧化及血管内皮炎症的影响。方法将200例CHD患者随机分为治疗组和对照组各100例。两组均给予常规西药治疗,治疗组在此基础上口服新血府逐瘀软胶囊,每次2g,每天3次,两组均治疗6个月。观察两组患者治疗前后血瘀征象,测量颈动脉内膜中层厚度(cIMT),检测血清氧化型低密度脂蛋白(ox-LDL)、超敏C反应蛋白(hs-CRP)、血清OX40L水平。结果两组血瘀征象均较治疗前改善,治疗组血瘀征象临床疗效有效率为83.1%、对照组为60.9%,两组比较差异有统计学意义(P<0.05);治疗后两组ox-LDL、hs-CRP、OX40L水平均较治疗前显著降低(P<0.05),治疗组较对照组降低明显(P<0.05);两组cIMT治疗前后及组间比较差异均无统计学意义(P>0.05)。结论新血府逐瘀软胶囊能改善CHD患者血瘀征象,抑制脂质过氧化,抗血管内皮炎症。

Objective To observe the effect of New Xuefu Zhuyu Soft Capsule （Blood Stasis-Expelling Soft Capsule） on the blood stasis syndrome, lipid peroxidation and vascular endothelial inflammation in patients with coronary heart disease （CHD）. Methods Two hundred cases of CHD were randomized into the treatment group and control group, with 100 in each. Both groups were given conventional western medicine for 6 months. The treatment group was added with New Xuefu Zhuyu Soft Capsule orally, 2g each time, 3 times daily. The signs of blood stasis syndrome, carotid artery intima-media thickness （cI- MT）, oxidized low density lipoprotein （ox-LDL）, high sensitivity C-reactive protein （hs-CRP） and serum OX40L were ob served before and after treatment. Results The signs of blood stasis syndrome in both groups were relieved after treatment. The effective rate of the treatment group and the control group was 83.1% and 60.9 % respectively, with significant difference between groups （P〈0.05）. The level of ox-LDL, hs-CRP and OX40L was significantly decreased in both groups after treatment （P〈0.05）, especially in the treatment group （P〈0.05）. There was no significant difference in cIMT between groups and in group （P〉0.05）. Conclusion New Xuefu Zhuyu Soft Capsule for CHD could relieve signs of blood stasis syndrome, inhibit lipid peroxidation and anti-vascular endothelial inflammation.